Issue 5/2021
Content (30 Articles)
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment
Xiaoping Song, Wei Tang, Hui Peng, Xin Qi, Jing Li
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers
Meng-Zhu Li, Tao Meng, Shan-Shan Song, Xu-Bin Bao, Lan-Ping Ma, Ning Zhang, Ting Yu, Yong-Liang Zhang, Bing Xiong, Jing-Kang Shen, Ze-Hong Miao, Jin-Xue He
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells
Jinbing Xue, Gang Wu, Umer Ejaz, Fahad Akhtar, Xinyu Wan, Yong Zhu, Aixing Geng, Yadong Chen, Shuying He
Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
Nurul A Abdullah, Martyn Inman, Christopher J. Moody, Sarah J Storr, Stewart G Martin
Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays
Xiaotong Chen, Yunshuo Zhao, Sifan Lyu, Guanfei Gao, Yanfeng Gao, Yuanming Qi, Jiangfeng Du
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model
Yuki Fujii, Hirofumi Kamachi, Fumihiko Matsuzawa, Tatsuzo Mizukami, Nozomi Kobayashi, Moto Fukai, Akinobu Taketomi
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models
Fanyi Meng, Yinshuang Chen, Man Yang, Hongjian Zhang, Weipeng Wang
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
María Eugenia Olmedo, Martin Forster, Victor Moreno, María Pilar López-Criado, Irene Braña, Michael Flynn, Bernard Doger, María de Miguel, José Antonio López-Vilariño, Rafael Núñez, Carmen Kahatt, Martin Cullell-Young, Ali Zeaiter, Emiliano Calvo
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Y. Dirix, Radka Obermannova, Jonathan E. Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua Sabari, Sonya Chapman, Wei Zhang, Boris Calderon, Daniel A. Peterson
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S. Pedersen, Patrick M. Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang-Gillam, Benjamin Tan
Effect of severe renal impairment on the pharmacokinetics of brigatinib
Neeraj Gupta, Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C. Marbury, Karthik Venkatakrishnan
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
Ming-Mo Hou, Ching-Liang Ho, Hsuan-Yu Lin, Yunting Zhu, Xiaodi Zhang
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
Sarina A. Piha-Paul, Analía Azaro, Hendrik Tobias Arkenau, Do-Youn Oh, Matthew D. Galsky, Sumanta Kumar Pal, Kensuke Hamada, Yaohua He, Ikuo Yamamiya, Karim A Benhadji, Antoine Hollebecque
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Filip Janku, Patricia LoRusso, Aaron S. Mansfield, Rita Nanda, Alexander Spira, Tianli Wang, Amal Melhem-Bertrandt, Jennifer Sugg, Howard A. Ball
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
Kyaw Zin Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Abdulrazzak Zarifa, Jatin Shah, Denái R. Milton, Stacie Bean, Lacey McQuinn, Jing Gong, Rivka Colen, Brett W. Carter, Vivek Subbiah, Deby C. Ogbonna, Shubham Pant, Funda Meric-Bernstam, Aung Naing
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
Jii Bum Lee, Minkyu Jung, Seung Hoon Beom, Gun Min Kim, Hye Ryun Kim, Hye Jin Choi, Joo Hyuk Sohn, Joong Bae Ahn, Sun Young Rha, Hyun Cheol Chung
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Stephen L. Chan, Paul N.M. Cheng, Angela M. Liu, Landon L. Chan, Leung Li, Cheuk M. Chu, Charing C.N. Chong, Yat M. Lau, Winnie Yeo, Kelvin K.C. Ng, Simon C.H. Yu, Tony S.K. Mok, Anthony W.H. Chan
The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma
Peng Yuan, Fei Wang, Guangyu Zhu, Baoan Chen
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
Hiroto Inoue, Akiko Todaka, Kentaro Yamazaki, Kunihiro Fushiki, Hiromichi Shirasu, Takeshi Kawakami, Takahiro Tsushima, Satoshi Hamauchi, Tomoya Yokota, Nozomu Machida, Akira Fukutomi, Yusuke Onozawa, Akira Andoh, Hirofumi Yasui
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial
Andrew W. Hahn, Jad Chahoud, Matthew T. Campbell, Daniel D. Karp, Jennifer Wang, Bettzy Stephen, Shi-Ming Tu, Curtis A. Pettaway, Aung Naing
Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review
Hui Su, Chao Yu, Xuezhen Ma, Qingcui Song
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation
Lin-ling Jin, Zhen-zhen Wu, Yan-li Wang, Dong-sheng Chen, Si Li, Mingzhe Xiao, Xin Zhao
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes
Masahide Fukudo, Keiko Asai, Chikayoshi Tani, Masashi Miyamoto, Katsuyoshi Ando, Nobuhiro Ueno
Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab
Yong Wang, Jun Xu, Ningning Luo, Chuang Qi, Rongjie Tao
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer
Ming-jun Zhang, Dong-sheng Chen, Si Li, Lin Chen, Ying-xue Qi, Cong-jun Zhang
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma
Chen Xiong, Zhihuai Wang, Guifu Wang, Chi Zhang, Shengjie Jin, Guoqing Jiang, Dousheng Bai
Author Correction to: Advances in anti-BRAF therapies for lung cancer
Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani